-
Media Release
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
-
Media Release
Novartis Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer
-
Story
A scientist from the start – Q&A with NIBR President Fiona Marshall -
Story
In neuroscience, “an inflection point in knowledge and technology” -
Media Release
Novartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases
-
Story
When it comes to cancer, there’s power in a good partner -
Story
Stopping this coronavirus – and the next one -
Story
Solving the puzzle of immunotherapy -
Media Release
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
-
Media Release
Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)
-
Media Release
Novartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisition
-
Media Release
Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients